In animal studies, treatment with recombinant human IL-35 led to an increase in both circulating and local Treg levels and a reduction in the plaque size in ApoE−/− mice, suggesting that IL-35 attenuates atherosclerosis via upregulating Treg immune response [53]. This evidence concerns the gene APOE and atherosclerosis.